Testing for ESR1 Mutations to Guide Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer …
HJ Burstein, A DeMichele, MR Somerfield… - Journal of Clinical …, 2023 - ascopubs.org
ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline
recommendations as a response to the emergence of new and practice-changing data. The …
recommendations as a response to the emergence of new and practice-changing data. The …
Chemotherapy and targeted therapy for human epidermal growth factor receptor 2–negative metastatic breast cancer that is either endocrine-pretreated or hormone …
ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline
recommendations as a response to the emergence of new and practice-changing data. The …
recommendations as a response to the emergence of new and practice-changing data. The …
Chemotherapy and targeted therapy for endocrine-pretreated or hormone receptor–negative metastatic breast cancer: ASCO guideline rapid recommendation update
ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline
recommendations as a response to the emergence of new and practice-changing data. The …
recommendations as a response to the emergence of new and practice-changing data. The …
Endocrine treatment and targeted therapy for hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer: ASCO …
HJ Burstein, MR Somerfield, DL Barton… - Journal of clinical …, 2021 - ascopubs.org
PURPOSE To update recommendations of the ASCO systemic therapy for hormone receptor
(HR)-positive metastatic breast cancer (MBC) guideline. METHODS An Expert Panel …
(HR)-positive metastatic breast cancer (MBC) guideline. METHODS An Expert Panel …
The Impact of ESR1 Mutations on the Treatment of Metastatic Breast Cancer
After nearly 20 years of research, it is now established that mutations within the estrogen
receptor (ER) gene, ESR1, frequently occur in metastatic breast cancer and influence …
receptor (ER) gene, ESR1, frequently occur in metastatic breast cancer and influence …
Systemic therapy for advanced human epidermal growth factor receptor 2–positive breast cancer: ASCO guideline update
SH Giordano, MAB Franzoi, S Temin… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE To update evidence-based guideline recommendations to practicing oncologists
and others on systemic therapy for patients with human epidermal growth factor receptor 2 …
and others on systemic therapy for patients with human epidermal growth factor receptor 2 …
Chemotherapy and targeted therapy for patients with human epidermal growth factor receptor 2–negative metastatic breast cancer that is either endocrine-pretreated …
PURPOSE This guideline updates recommendations of the ASCO guideline on
chemotherapy and targeted therapy for patients with human epidermal growth factor …
chemotherapy and targeted therapy for patients with human epidermal growth factor …
Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2–negative (or unknown) advanced breast cancer: American Society of …
Purpose To identify optimal chemo-and targeted therapy for women with human epidermal
growth factor 2 (HER2)–negative (or unknown) advanced breast cancer. Methods A …
growth factor 2 (HER2)–negative (or unknown) advanced breast cancer. Methods A …
Prevalence of ESR1 mutations in cell-free DNA and outcomes in metastatic breast cancer: a secondary analysis of the BOLERO-2 clinical trial
S Chandarlapaty, D Chen, W He, P Sung… - JAMA …, 2016 - jamanetwork.com
Importance Estrogen receptor α (ESR1) mutations found in metastatic breast cancer (MBC)
promote ligand-independent receptor activation and resistance to estrogen-deprivation …
promote ligand-independent receptor activation and resistance to estrogen-deprivation …
Comparative analysis of human epidermal growth factor receptor 2 testing in breast cancer according to 2007 and 2013 American Society of Clinical Oncology …
WM Hanna, E Slodkowska, FI Lu, H Nafisi… - Journal of Clinical …, 2017 - ascopubs.org
Purpose To study the effect of the 2013 updates to the 2007 American Society of Clinical
Oncology/College of American Pathologists recommendations for human epidermal growth …
Oncology/College of American Pathologists recommendations for human epidermal growth …
相关搜索
- breast cancer asco guideline
- hormone receptor asco guideline
- growth factor asco guideline
- esr1 mutations asco guideline
- growth factor breast cancer
- hormone receptor breast cancer
- esr1 mutations breast cancer
- hormone receptor esr1 mutations
- hormone receptor growth factor
- growth factor esr1 mutations
- breast cancer systemic therapy
- growth factor systemic therapy
- breast cancer american society
- growth factor american society
- breast cancer endocrine treatment
- breast cancer secondary analysis